Study of DNA in Blood Samples From Patients With Neuroblastoma
Recruitment status was Active, not recruiting
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This laboratory study is looking at DNA in blood samples from patients with neuroblastoma.
Genetic: polymerase chain reaction
Genetic: reverse transcriptase-polymerase chain reaction
Other: diagnostic laboratory biomarker analysis
|Official Title:||Analysis of Circulating MYCN DNA in Serum Samples Obtained From Patients With Neuroblastoma|
- Most appropriate MYCN/control ratio cutoff capable of determining positive and negative cases of neuroblastoma [ Designated as safety issue: No ]
- Limits of the procedure in non-metastatic patients and in those with reduced tumor burden [ Designated as safety issue: No ]
|Study Start Date:||June 2007|
- Perform in a blind study a multicentric study by analyzing serum from patients at diagnosis (with a known tumour MYCN status determined in the COG reference lab), in order to confirm our previous data and to define the most appropriate MYCN/control ratio cutoff capable of determining positive and negative cases.
- Define the limits of the procedure in non-metastatic patients and in those with reduced tumor burden (INSS stage 1 and 2).
OUTLINE: Circulating DNA is extracted from serum. PCR amplification of MYCN is performed and analyzed by agarose gel electrophoresis. Real-time quantitative PCR is also performed.
|Study Chair:||Michael D. Hogarty, MD||Children's Hospital of Philadelphia|